Last reviewed · How we verify
ACE Inhibitors and Calcium Channel Blockers
ACE Inhibitors and Calcium Channel Blockers is a Small molecule drug developed by Istanbul Nisantasi University. It is currently in Phase 2 development. Also known as: NSAID.
At a glance
| Generic name | ACE Inhibitors and Calcium Channel Blockers |
|---|---|
| Also known as | NSAID |
| Sponsor | Istanbul Nisantasi University |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- cough
- arterial hypotension with BP of 80/50 mm Hg and weakness
- treatment inefficacy
- unstable angina
- arterial hypotension
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- The GUARDIAN Pilot Trial (NA)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk (NA)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- A Study of Blood Pressure Control During Cancer Treatment (PHASE2)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Preventing Cognitive Decline by Reducing BP Target Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACE Inhibitors and Calcium Channel Blockers CI brief — competitive landscape report
- ACE Inhibitors and Calcium Channel Blockers updates RSS · CI watch RSS
- Istanbul Nisantasi University portfolio CI
Frequently asked questions about ACE Inhibitors and Calcium Channel Blockers
What is ACE Inhibitors and Calcium Channel Blockers?
ACE Inhibitors and Calcium Channel Blockers is a Small molecule drug developed by Istanbul Nisantasi University.
Who makes ACE Inhibitors and Calcium Channel Blockers?
ACE Inhibitors and Calcium Channel Blockers is developed by Istanbul Nisantasi University (see full Istanbul Nisantasi University pipeline at /company/istanbul-nisantasi-university).
Is ACE Inhibitors and Calcium Channel Blockers also known as anything else?
ACE Inhibitors and Calcium Channel Blockers is also known as NSAID.
What development phase is ACE Inhibitors and Calcium Channel Blockers in?
ACE Inhibitors and Calcium Channel Blockers is in Phase 2.
What are the side effects of ACE Inhibitors and Calcium Channel Blockers?
Common side effects of ACE Inhibitors and Calcium Channel Blockers include cough, arterial hypotension with BP of 80/50 mm Hg and weakness, treatment inefficacy, unstable angina, arterial hypotension.
Related
- Manufacturer: Istanbul Nisantasi University — full pipeline
- Also known as: NSAID
- Compare: ACE Inhibitors and Calcium Channel Blockers vs similar drugs
- Pricing: ACE Inhibitors and Calcium Channel Blockers cost, discount & access